Transformational cell therapies for patients with pancreatic disease

OUR PIPELINE OF CELL THERAPIES IS CHANGING THE OUTLOOK FOR PATIENTS WITH CHRONIC PANCREATITIS AND TYPE 1 DIABETES.

Matthew Lehman,

Chief Executive Officer (Koligo Therapeutics Inc.) and Executive Director

  • Proven biotech & cell therapy executive
  • NASDAQ-listed Prima Biomed, CSE-listed M Pharmaceutical, private CRO SPRI Clinical Trials
  • Clinical research & manufacturing scale-up expertise
  • MS Columbia; BA Louisville

Stuart Williams, PhD,

Chief Technology Officer (Koligo Therapeutics Inc.) and Executive Director

  • Division chief, Bioficial Heart, Cardiovascular Innovation Institude
  • 300+ publications & 16 issued US patents in cell & tissue engineering
  • Experienced academic-industry partner: founded three biotech companies
  • PhD cell biology University of Delaware, postdoc Yale School of Medicine